Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers

被引:105
作者
Beletsi, A [1 ]
Panagi, Z [1 ]
Avgoustakis, K [1 ]
机构
[1] Univ Patras, Dept Pharm, Pharmaceut Technol Lab, Patras 26500, Greece
关键词
poly(lactide-co-glycolide)/poly(lactide-co-glycolide)-poly(ethylene glycol) nanoparticles; biodistribution; physicochemical characteristics;
D O I
10.1016/j.ijpharm.2005.03.024
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The basic characteristics and the biodistribution properties of nanoparticles prepared from mixtures of poly(lactide-co-glycolide) (PLGA) with poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) copolymers were investigated. A PLGA(45)-PEG(5) copolymer of relatively low PEG content and a PLGA(5)-PEG(5) copolymer of relatively high PEG content were included in the study. Increasing the PLGA-PEG content of the PLGA/PLGA-PEG mixture, or when PLGA(45)-PEG(5) was replaced by PLGA(5)-PEG(5), a decrease in the size of the nanoparticles and an increase in the rate of PEG loss from the nanoparticles were observed. The blood residence of the PLGA/PLGA(45)-PEG(5) nanoparticles increased as their PLGA-PEG content was increased, reaching maximum blood longevity at 100% PLGA(45)-PEG(5). On the contrary, the blood residence of PLGA/PLGA(5)-PEG(5) nanoparticles exhibited a plateau maximum in the range of 80-100% PLGA(5)-PEG(5). At PLGA-PEG proportions lower than 80%, the PLGA/PLGA(45)-PEG(5) nanoparticles exhibited lower blood residence than the PLGA/PLGA(5)-PEG(5) nanoparticles, whereas at PLGA-PEG proportions higher than 80%, the PLGA/PLGA(45)-PEG(5) nanoparticles exhibited higher blood residence than the PLGA/PLGA(5)-PEG(5) nanoparticles. These findings indicate that apart from the surface PEG content, the biodistribution properties of the PLGA/PLGA-PEG nanoparticles are also influenced by the size of the nanoparticles and the rate of PEG loss from the nanoparticles. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 23 条
[1]   Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles [J].
Avgoustakis, K ;
Beletsi, A ;
Panagi, Z ;
Klepetsanis, P ;
Livaniou, E ;
Evangelatos, G ;
Ithakissios, DS .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 259 (1-2) :115-127
[2]   PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in Vivo drug residence in blood properties [J].
Avgoustakis, K ;
Beletsi, A ;
Panagi, Z ;
Klepetsanis, P ;
Karydas, AG ;
Ithakissios, DS .
JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :123-135
[3]  
Avgoustakis Konstantinos, 2004, Current Drug Delivery, V1, P321, DOI 10.2174/1567201043334605
[4]   STEALTH ME.PEG-PLA NANOPARTICLES AVOID UPTAKE BY THE MONONUCLEAR PHAGOCYTES SYSTEM [J].
BAZILE, D ;
PRUDHOMME, C ;
BASSOULLET, MT ;
MARLARD, M ;
SPENLEHAUER, G ;
VEILLARD, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (04) :493-498
[5]   Effect of preparative variables on the properties of poly(dl-lactide-co-glycolide) methoxypoly(ethyleneglycol) copolymers related to their application in controlled drug delivery [J].
Beletsi, A ;
Leontiadis, L ;
Klepetsanis, P ;
Ithakissios, DS ;
Avgoustakis, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 182 (02) :187-197
[6]  
DAVIS SS, 1994, TARGETING DRUGS, V4, P183
[7]   Formulation and lyoprotection of poly(lactic acid-co-ethylene oxide) nanoparticles:: Influence on physical stability and in vitro cell uptake [J].
De Jaeghere, F ;
Allémann, E ;
Leroux, JC ;
Stevels, W ;
Feijen, J ;
Doelker, E ;
Gurny, R .
PHARMACEUTICAL RESEARCH, 1999, 16 (06) :859-866
[8]   Lidocaine-loaded biodegradable nanospheres.: I.: Optimization of the drug incorporation into the polymer matrix [J].
Görner, T ;
Gref, R ;
Michenot, D ;
Sommer, F ;
Tran, MN ;
Dellacherie, E .
JOURNAL OF CONTROLLED RELEASE, 1999, 57 (03) :259-268
[9]   'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG):: influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption [J].
Gref, R ;
Lück, M ;
Quellec, P ;
Marchand, M ;
Dellacherie, E ;
Harnisch, S ;
Blunk, T ;
Müller, RH .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2000, 18 (3-4) :301-313
[10]   THE CONTROLLED INTRAVENOUS DELIVERY OF DRUGS USING PEG-COATED STERICALLY STABILIZED NANOSPHERES [J].
GREF, R ;
DOMB, A ;
QUELLEC, P ;
BLUNK, T ;
MULLER, RH ;
VERBAVATZ, JM ;
LANGER, R .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (2-3) :215-233